Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: A critical review

Abe, 2001, Peripheral blood fibrocytes: differentiation pathway and migration to wound sites, J. Immunol., 166, 7556, 10.4049/jimmunol.166.12.7556 Abraham, 2008, Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis, Br. J. Dermatol., 158, 273, 10.1111/j.1365-2133.2007.08335.x Adding, 2001, Basic experimental studies and clinical aspects of gadolinium salts and chelates, Cardiovasc. Drugs Rev., 19, 41, 10.1111/j.1527-3466.2001.tb00182.x Aime, 2007, Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate, Kidney Int., 72, 1161, 10.1038/sj.ki.5002503 Bellin, 2003, Currently used non-specific extracellular MR contrast media, Eur. Radiol., 13, 2688, 10.1007/s00330-003-1912-x Bianchi, 1999, Interaction of ATP with a Gd3+ complex employed as paramagnetic contrast agent in NMR imaging, Inorg. Chim. Acta, 288, 244, 10.1016/S0020-1693(99)00106-1 Bongartz, 2007, Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?, Magma, 20, 57, 10.1007/s10334-007-0071-5 Boyd, 2007, Gadolinium deposition in nephrogenic fibrosing dermopathy, J. Am. Acad. Dermatol., 56, 27, 10.1016/j.jaad.2006.10.048 Broome, 2007, Response to “Gadodiamide-associated nephrogenic systemic fibrosis”, Am. J. Roentgenol., 188, W585, 10.2214/AJR.07.0191 Broome, 2007, Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned, Am. J. Roentgenol., 188, 586, 10.2214/AJR.06.1094 Brücher, 2002, Kinetic stability of gadolinium (III) chelates used as MRI contrast agents, vol. 221 Brücher, 2001, Stability and toxicity of contrast agents, 243 Bucala, 2007, Fibrocytes: discovery of a circulating connective tissue cell progenitor, 1 Bucala, 1994, Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair, Mol. Med., 1, 71, 10.1007/BF03403533 Cacheris, 1990, The relationship between thermodynamics and the toxicity of gadolinium complexes, Magn. Reson. Imaging, 8, 467, 10.1016/0730-725X(90)90055-7 Chesney, 1997, The peripheral blood fibrocytes is a potent antigen-presenting cell capable of priming naive T cells in situ, Proc. Natl. Acad. Sci. U.S.A., 94, 6307, 10.1073/pnas.94.12.6307 Collidge, 2007, Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort, Radiology, 245, 168, 10.1148/radiol.2451070353 Corot, 1998, Structure–activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme, J. Magn. Reson. Imaging, 8, 695, 10.1002/jmri.1880080328 Cowper, 2003, Nephrogenic fibrosing dermopathy: the first 6 years, Curr. Opin. Rheumatol., 15, 785, 10.1097/00002281-200311000-00017 Cowper, 2007, Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium, Adv. Dermatol., 23, 131, 10.1016/j.yadr.2007.07.002 Cowper, 2006, Nephrogenic systemic fibrosis: an update, Curr. Rheumatol. Rep., 8, 151, 10.1007/s11926-006-0056-9 Cowper, 2000, Scleromyxoedema-like cutaneous diseases in renal-dialysis patients, Lancet, 356, 1000, 10.1016/S0140-6736(00)02694-5 Dardenne, 2002, Zinc and immune function, Eur. J. Clin. Nutr., 56, S20, 10.1038/sj.ejcn.1601479 De Broe, 2008, Can the risk of gadolinium be extrapolated to lanthanum?, Semin. Dial., 21, 142, 10.1111/j.1525-139X.2007.00416.x Desreux, 1980, Nuclear magnetic resonance spectroscopy of lanthanide complexes with a tetraacetic-tetraaza macrocycle. Unusual conformation properties, Inorg. Chem., 19, 1319, 10.1021/ic50207a042 Döhr, 2007, Preclinical safety evaluation of Gd-EOB-DTPA (Primovist), Invest. Radiol., 42, 830, 10.1097/RLI.0b013e318137a471 Edward, 2007, Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum, Br. J. Dermatol., 156, 473, 10.1111/j.1365-2133.2006.07652.x Edward, 2008, Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis, J. Pathol., 214, 584, 10.1002/path.2311 Evenepoel, 2004, Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure, Nephrol. Dial. Transplant., 19, 469, 10.1093/ndt/gfg506 Fathke, 2004, Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair, Stem Cells, 22, 812, 10.1634/stemcells.22-5-812 Fisher, 2003, Erythropoietin: physiology and pharmacology update, Exp. Biol. Med., 228, 1, 10.1177/153537020322800101 Frenzel, 2008, Stability of gadolinium-based contrast agents in human serum, Eur. Radiol., 18, 162 Galan, 2006, Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), Curr. Opin. Rheumatol., 18, 614, 10.1097/01.bor.0000245725.94887.8d Goddard, 2007, Nephrogenic fibrosing dermopathy with recurrence after allograft failure, J. Am. Acad. Dermatol., 56, S109, 10.1016/j.jaad.2006.04.061 Goveia, 2007, Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis, J. Am. Acad. Dermatol., 57, 725, 10.1016/j.jaad.2007.07.010 Griffin, 2002, Transglutaminases: nature's biological glues, Biochem. J., 368, 377, 10.1042/bj20021234 Grobner, 2006, Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic systemic fibrosis?, Nephrol. Dial. Transplant., 21, 1104, 10.1093/ndt/gfk062 Günzel, 1992, Toxicology of contrast media for magnetic resonance imaging. A brief review, Adv. MRI Contrast, 1, 29 Haroon, 2003, A novel role for erythropoietin during fibrin-induced wound-healing response, Am. J. Pathol., 163, 993, 10.1016/S0002-9440(10)63459-1 Harpur, 1993, Preclinical safety assessment and phamacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent, Invest. Radiol., 28, S28, 10.1097/00004424-199303001-00004 Harrison, 1993, Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids, Magn. Reson. Imaging, 11, 761, 10.1016/0730-725X(93)90194-I High, 2007, Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis, J. Am. Acad. Dermatol., 56, 21, 10.1016/j.jaad.2006.10.047 High, 2007, Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis, J. Am. Acad. Dermatol., 56, 710, 10.1016/j.jaad.2007.01.022 Ide, 2005, Effects of gadolinium chloride (GdCl3) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions, J. Comp. Pathol., 133, 92, 10.1016/j.jcpa.2005.01.011 Idée, 2006, Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review, Fundam. Clin. Pharmacol., 20, 563, 10.1111/j.1472-8206.2006.00447.x Itoh, 1984, Characterization of Gd3+ and Tb3+ binding sites on Ca2+ Mg2+ – adenosine triphosphatase of sarcoplasmic reticulum, J. Biochem. (Tokyo), 95, 661, 10.1093/oxfordjournals.jbchem.a134655 Jain, 2004, Nephrogenic fibrosing dermopathy in pediatric patients, Pediatr. Nephrol., 19, 467, 10.1007/s00467-003-1380-1 Joffe, 1998, Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis, Acad. Radiol., 5, 491, 10.1016/S1076-6332(98)80191-8 Kanal, 2007, ACR guidance document for safe MR practices: 2007, Am. J. Roentgenol., 188, 1, 10.2214/AJR.06.1616 Kanal, 2008, Response to the FDA's May 23 2007, nephrogenic systemic fibrosis update, Radiology, 246, 11, 10.1148/radiol.2461071267 Khanna, 1997, In vivo hyperexpression of transforming growth-factor-beta 1 in mice: stimulation by cyclosporine, Transplantation, 63, 1037, 10.1097/00007890-199704150-00026 Kim, 2006, Transglutaminase 2 in inflammation, Front. Biosci., 11, 3026, 10.2741/2030 Kumar, 1997, Macrocyclic polyamino carboxylate complexes of Gd (III) as magnetic resonance imaging contrast agents, J. Alloys Comp., 249, 163, 10.1016/S0925-8388(96)02644-8 Kumar, 1993, Equilibrium and kinetic studies of lanthanide complexes of macrocyclic polyamino carboxylates, Inorg. Chem., 32, 587, 10.1021/ic00057a017 Kumar, 1995, Synthesis, stability, and crystal structure studies of some Ca2+, Cu2+, and Zn2+ complexes of macrocyclic polyamino carboxylates, Inorg. Chem., 34, 6472, 10.1021/ic00130a012 Kuo, 2007, Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis, Radiology, 242, 647, 10.1148/radiol.2423061640 Larivière, 2003, Endothelin-1 in chronic renal failure and hypertension, Can. J. Physiol. Pharmacol., 81, 607, 10.1139/y03-012 Laurent, 2001, Stability of MRI paramagnetic contrast media. A proton relaxometric protocol for transmetallation assessment, Invest. Radiol., 36, 115, 10.1097/00004424-200102000-00008 Laurent, 2006, Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents, Contrast Med. Mol. Imaging, 1, 128, 10.1002/cmmi.100 Marckmann, 2006, Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging, J. Am. Soc. Nephrol., 17, 2359, 10.1681/ASN.2006060601 Marckmann, 2007, Case–control study of gadodiamide-related nephrogenic systemic fibrosis, Nephrol. Dial. Transplant., 22, 3174, 10.1093/ndt/gfm261 Mehran, 2006, Contrast-induced nephropathy: definition, epidimiology, and patients at risk, Kidney Int., 69, S11, 10.1038/sj.ki.5000368 Mendoza, 2006, Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature, Semin. Arthritis Rheum., 35, 238, 10.1016/j.semarthrit.2005.08.002 Meyer, 1988, Gd-DOTA, a potential MRI contrast agent, Current status of physicochemical knowledge, Invest. Radiol., 23, S232, 10.1097/00004424-198809000-00050 Morcos, 2007, Nephrogenic systemic fibrosis following the administration of extracellular gadolinium-based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?, Br. J. Radiol., 80, 73, 10.1259/bjr/17111243 Moreau, 2004, Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis (carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota). Characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS, Chem. Eur. J., 10, 5218, 10.1002/chem.200400006 Oka, 2007, Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage, Ther. Apher. Dial., 11, 107, 10.1111/j.1744-9987.2007.00432.x Othersen, 2007, Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure, Nephrol. Dial. Transplant., 22, 3179, 10.1093/ndt/gfm584 Palasz, 2000, Toxicological and cytophysiological aspects of lanthanides action, Acta Biochim. Pol., 47, 1107, 10.18388/abp.2000_3963 Paniagua-Sierra, 1981, Zinc and copper concentrations in plasma and erythrocytes of patients of chronic renal failure, Arch. Invest. Med. (Mex.), 12, 69 Parsons, 2007, Transglutaminases: the missing link in nephrogenic systemic fibrosis, Am. J. Dermatopathol., 29, 433, 10.1097/DAD.0b013e318156e43f Perazella, 2007, Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?, Clin. J. Am. Soc. Nephrol., 2, 200, 10.2215/CJN.00030107 Phillips, 2004, Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis, J. Clin. Invest., 114, 438, 10.1172/JCI200420997 Pilling, 2003, Inhibition of fibrocytes differentiation by serum amyloid P, J. Immunol., 171, 5537, 10.4049/jimmunol.171.10.5537 Pollet, 2007, Ab initio simulation of a gadolinium-based magnetic resonance imaging contrast agent in aqueous solution, J. Chem. Phys., 126, 181102, 10.1063/1.2736369 Port, M., Idée, J.M., Medina, C., Robic, C., Sabatou, M., Corot, C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals, in press. Prasad, 1985, Clinical manifestations of zinc deficiency, Annu. Rev. Nutr., 5, 341, 10.1146/annurev.nu.05.070185.002013 Priyadarshi, 2006, Erythropoietin resistance in the treatment of the anemia of chronic renal failure, Sem. Dial., 19, 273, 10.1111/j.1525-139X.2006.00172.x Pulukkody, 1993, Synthesis of charged and uncharged complexes of gadolinium and yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications, J. Chem. Soc. Perkin Trans., 2, 605, 10.1039/p29930000605 Puttagunta, 1996, Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents, Invest. Radiol., 31, 739, 10.1097/00004424-199612000-00001 Rydahl, 2008, High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent, Invest. Radiol., 43, 141, 10.1097/RLI.0b013e31815a3407 Saab, 2008, Epoietin and nephrogenic systemic fibrosis, J. Am. Acad. Dermatol., 58, 174, 10.1016/j.jaad.2007.10.012 Saab, 2007, Nephrogenic systemic fibrosis: a nephrologist's perspective, Hemodial. Int., 11, S2, 10.1111/j.1542-4758.2007.00222.x Sadowski, 2007, Nephrogenic systemic fibrosis: risk factors and incidence estimation, Radiology, 243, 148, 10.1148/radiol.2431062144 Sakai, 1998, Fluid shear stress increases transforming growth factor beta-1 expression in human osteoblast-like cells: modulation by cation channel blockade, Calcif. Tissue Int., 63, 515, 10.1007/s002239900567 Sarka, 2000, The rates of the exchange reactions between [Gd(DTPA)]2- and the endogenous ions Cu2+ and Zn2+: a kinetic model for the prediction of the in vivo stability of [Gd(DTPA)]2-, used as a contrast agent in magnetic resonance imaging, Chem. Eur. J., 6, 719, 10.1002/(SICI)1521-3765(20000218)6:4<719::AID-CHEM719>3.0.CO;2-2 Saussereau, 2008, Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis, Forensic Sci. Int., 176, 54, 10.1016/j.forsciint.2008.01.007 Shellock, 1999, Safety of magnetic resonance imaging contrast agents, J. Magn. Reson. Imaging, 10, 477, 10.1002/(SICI)1522-2586(199909)10:3<477::AID-JMRI33>3.0.CO;2-E Shi, 2003, l-homocysteine sulfinic acid and other acidic homocystein homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists, J. Pharmacol. Exp. Ther., 305, 131, 10.1124/jpet.102.047092 Sieber, 2008, A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media, Invest. Radiol., 43, 65, 10.1097/RLI.0b013e31815e6277 Signorini, 1988, Human erythrocyte transglutaminase: purification and preliminary characterization, Biol. Chem. Hoppe-Seyler, 369, 275, 10.1515/bchm3.1988.369.1.275 Spencer, 1997, Gadolinium chloride toxicity in the rat, Toxicol. Pathol., 25, 245, 10.1177/019262339702500301 Steger-Hartmann, 2006, Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new magnetic resonance imaging contrast agent for angiography, Invest. Radiol., 41, 449, 10.1097/01.rli.0000208223.34203.49 Swaminathan, 2007, New insights into nephrogenic systemic fibrosis, J. Am. Soc. Nephrol., 18, 2636, 10.1681/ASN.2007060645 Swaminathan, 2006, Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy, Ann. Intern. Med., 145, 234, 10.7326/0003-4819-145-3-200608010-00021 Swaminathan, 2007, Nephrogenic systemic fibrosis, gadolinium, and iron mobilization, New Engl. J. Med., 357, 720, 10.1056/NEJMc070248 Swernerton, 1968, Severe zinc deficiency in male and female rats, J. Nutr., 95, 8, 10.1093/jn/95.1.8 Thakral, 2007, Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications, Contrast Media Mol. Imaging, 2, 199, 10.1002/cmmi.146 Thomsen, 2006, Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide, Eur. Radiol., 16, 2619, 10.1007/s00330-006-0495-8 Tóth, 1994, Kinetics of formation and dissociation of lanthanide(III)-DOTA complexes, Inorg. Chem., 33, 4070, 10.1021/ic00096a036 Tóth, 1996, Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate, Inorg. Acta, 249, 191, 10.1016/0020-1693(96)05094-3 Tweedle, 1992, Physicochemical properties of gadoteridol and other magnetic resonance contrast agents, Invest. Radiol., 27, S2, 10.1097/00004424-199208001-00002 Tweedle, 1991, Reaction of gadolinium chelates with endogenously available ions, Magn. Reson. Imaging, 9, 409, 10.1016/0730-725X(91)90429-P Tweedle, 1995, Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate and gadodiamide in mice and rats, Invest. Radiol., 30, 372, 10.1097/00004424-199506000-00008 Uggeri, 1995, Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln=Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinite(2-) in a mixture with its enantiomer, Inorg. Chem., 34, 633, 10.1021/ic00107a017 Verrechia, 2007, Transforming growth factor-β and fibrosis, World J. Gastroenterol., 13, 3056, 10.3748/wjg.v13.i22.3056 Wedeking, 1992, Dissociation of gadolinium chelates in mice: relationship to chemical characteristics, Magn. Reson. Imaging, 10, 641, 10.1016/0730-725X(92)90016-S White, 2006, Comparison of Gd-(DTPA-BMA) (Omniscan) versus Gd-(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy, Invest. Radiol., 41, 272, 10.1097/01.rli.0000186569.32408.95 Wible, 2001, Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging, Invest. Radiol., 36, 401, 10.1097/00004424-200107000-00006 Wiginton, 2008, Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue, AJR, 190, 1, 10.2214/AJR.07.2822 Yerram, 2007, Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure. Role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate, Clin. J. Am. Soc. Nephrol., 2, 258, 10.2215/CJN.03250906